Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health    CVS

CVS HEALTH (CVS)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CET
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH
11/16 CVS HEALTH : Makes Overdose-Reversal Drug Available Without Individual Prescript..
11/16 CVS HEALTH : Earns Perfect Score in 2018 Corporate Equality Index
11/16 CVS HEALTH : Surescripts Transforms Prescription Decision Process Between Physic..
11/15 CVS HEALTH : delivering next-day service come the new year
11/15 Bayer hires new blood to stem 'Amazon effect' in consumer health
11/15 CVS HEALTH : Delaware, CVS Health make overdose reversal drug available without ..
11/14 CVS HEALTH : Commits to Hiring 5,000 New Apprentices by 2022, Expands States Par..
11/13 CVS HEALTH : Ensuring Our Veterans Have Access to Care
11/11 CVS HEALTH : will offer overdose reversal drug naloxone without prescription
11/10 CVS HEALTH : Public Health and CVS Health Make Overdose-Reversal Drug Available ..
More news
News from SeekingAlpha
03:46a 40 Dividend Stocks Battling Into 2018
12:28a DIVIDEND CONTENDERS : 24 Increases Expected In The Next 11 Weeks
11/16 Who Is Afraid Of Big Bad Amazon?
11/16 CVS : Undervalued
11/16 GREEN DOT PORTFOLIO : Part 2 - Inside The Portfolio
Financials ($)
Sales 2017 184 B
EBIT 2017 9 954 M
Net income 2017 5 242 M
Debt 2017 24 377 M
Yield 2017 2,78%
P/E ratio 2017 13,99
P/E ratio 2018 12,11
EV / Sales 2017 0,52x
EV / Sales 2018 0,50x
Capitalization 71 173 M
Chart CVS HEALTH
Duration : Period :
CVS Health Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Technical analysis trends CVS HEALTH
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 84,5 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH-11.54%71 173
WALGREENS BOOTS ALLIANCE-15.18%71 981
EXPRESS SCRIPTS HOLDING CO-12.71%35 370
MCKESSON CORPORATION1.60%29 749
CARDINAL HEALTH INC-21.04%18 100
AMERISOURCEBERGEN CORP.-0.84%17 597